ABSTRACT
Objective To explore the application value of CEUS in diagnosis of renal occupying lesions.Methods Totally 67 patients with renal occupying lesions underwent conventional ultrasound and CEUS before surgical operation.CEUS enhancement characteristics were observed and compared between 40 patients with clear cell renal cell carcinoma (CCRCC)and 14 patients with angiomyolipoma (AML).Meanwhile the time-intensity curves were analyzed,including peak intensity (IMAX),rise time (RT),time-to-peak time (TTP) and mean transit time (mTT).Results There were significant differences in enhancement patterns,degrees,homogeneity of enhancement and pseudocapsule sign between CCRCC and AML (all P＜0.01).Compared with AML,IMAX of CCRCC was higher,RT and mTT were both earlier (P＜0.05).The sensitivity,specificity and accuracy of CEUS in diagnosis of malignant renal occupying lesions was 91.49 ％ (43/47),75.00 ％(15/20) and 86.57％ (58/67),respectively.Conclusion CEUS combined with quantitative analysis software is helpful to diagnosis and identification of CCRCC and AML.
ABSTRACT
Objective To discuss application value for detecting sentinel lymphatic node(SLN) in patients with breast mass by subcutaneous injection SonoVue. Methods Forty-two cases with breast masses who were detected by conventional techniques were injected subcutaneously with 1.25 ml Sono Vue to the borderline of breast tumor at each 3,6,9, 12 points. The changes of contrast-enhanced ultrasound (CEUS) of the ipsilateral axillary SLN were observed and the start time of enhancement of lymphatic channel and lymph nodes, the position and numbers of enhancement of the lymph nodes, the time of regression were recorded. Compared with Methylene blue and surgicalbiopsy, the accuracy of detection of SLN by CEUS were evaluated. Results SLN were successfully detected in 30 of 42 patients, the detection rate was 71.4%. The total number of detected SLN was 40.Five nodes were detected in 5 of 10 (50%)patients with benign masses. Thirty-five nodes were detected in 25 of 32 (78.1%) patients with breast cancer. Fifty-seven SLN were successfully detected in 39 of 42 patients with Methylene blue, the accurate rate was 92.9%. Seven of 10 patients with benign masses and all 32 patients with breast cancer were Methylene blue positive. There were total 64 SLN found, including 11 with benign masses and 53 with lymph nodes metastasis of breast cancer cells. Conclusions The subcutaneous injection SonoVue is effective to detect SLN in patients with breast mass and apply clinical value for forecasting whether the lymph node metastases in patients with breast cancer.